TITLE

Multiple sclerosis treatment trial precipitates divorce

AUTHOR(S)
COLES, A.; DEANS, J.; COMPSTON, A.
PUB. DATE
January 2001
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Jan2001, p135
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
67027757

 

Related Articles

  • Cannabis MS benefits 'subjective'  // Pulse;11/10/2003, Vol. 63 Issue 45, p7 

    Reports on the results of the randomized trial on cannabinoids as a treatment for multiple sclerosis in Great Britain. Mechanism underlying the treatment's action; Capacity of the treatment to improve mobility and pain control in multiple sclerosis; Safety profile in terms of general adverse events.

  • A major step in the treatment of MS. Cerrato, Paul L. // RN;Aug96, Vol. 59 Issue 8, p65 

    Presents the Interferon beta-1a, a drug used for the treatment of multiple sclerosis. Clinical trials; Recommended dose.

  • Late Breaking News 1.  // Multiple Sclerosis Journal;Oct2012 Supplement, Vol. 18 Issue 4, p509 

    The article presents abstracts on multiple sclerosis which include novel autoantigen in neuromyelitis optica spectrum disorder, the phase three trial on the efficacy and safety of glatiramer acetate injections, and natalizumab treatment of progressive multiple sclerosis.

  • Multiple sclerosis drug approved.  // Executive Health's Good Health Report;Feb97, Vol. 33 Issue 5, p8 

    Focuses on the US Food and Drug Administration's approval of Copaxone for the treatment of relapsing-remitting multiple sclerosis (MS). Features of the drug; Results of clinical trials of the drug; Difference to previous classes of multiple sclerosis drugs.

  • R&D UPDATE: Multiple Sclerosis.  // PharmaWatch: CNS;February 2003, Vol. 2 Issue 2, p5 

    Reports on developments relating to the treatment of multiple sclerosis. Reduction in the inflammatory brain lesions and relapses in patients with relapsing forms of multiple sclerosis by Antegren, a drug co-developed by Biogen and Elan; Start of Ilex Oncology's phase II trial comparing Campath...

  • Multiple Sclerosis Update.  // PharmaWatch: CNS;Jun2005, Vol. 4 Issue 6, p7 

    The article offers information about the treatment of multiple sclerosis in the U.S. The follow-up study of Chiron and Berlex named 16-LTF revealed that Betaseron, a multiple sclerosis treatment, is safe and effective for long-term use. Researchers have discovered the link between cigarette...

  • Promising results in early Antegren trial.  // Inside MS;Winter2002, Vol. 20 Issue 1, p36 

    Reports on the result of an early double-blind clinical trial of Antegren as announced at the 7th Congress of the European Committee on Treatment and Research in Multiple Sclerosis on September 15, 2001. Number of multiple sclerosis patients who participated in the trial; Effects of Antegren;...

  • Acorda completes enrolment for Phase III MS trial.  // PharmaWatch: CNS;Jan2008, Vol. 7 Issue 1, p6 

    The article reports that biotechnology company Acorda Therapeutics Inc. has completed enrollment for its Phase III clinical trial of Fampridine-SR for the treatment of multiple sclerosis. The trial is designed to evaluate the safety and effectiveness of Fampridine-SR in multiple sclerosis....

  • Research horizons: Treatments for progressive MS.  // Inside MS;Summer97, Vol. 15 Issue 2, p19 

    Discusses research in the treatment of progressive multiple sclerosis. Trials of drugs including Betaseron, Rebif, Avonex; Findings in peptide therapy; T cell vaccination.

  • Adverse Reaction Research.  // Reactions Weekly;11/17/2012, Issue 1428, p4 

    The article reports on a clinical trial data on the safety of dalfampridine, Ampyra, which was presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics